Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA/CD70 CAR-T in MDR-SRNS
NCT06553898Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD70 CAR-T cells in nephrotic syndrome, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Safety of CAR-T cell therapy at 3 months. Started Aug 2024; status: recruiting.
02
Drugs
CD70 CAR-T cells
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT06553898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553898.